Showing 8211-8220 of 9426 results for "".
- Viscot Offers New White Ink Markershttps://practicaldermatology.com/news/20140717-viscot_offers_new_white_ink_markers/2459165/Viscot Medical introduced White E•Z Removable Ink™to complement their existing green and red E•Z Removable Ink™ markers. E•Z Removable Ink™ comes off easily with an alcohol swab or water. E•Z Removable Ink™ eliminates the problem of patient
- Promius Pharma Launches New Physician Portal to Track Patient Progress on Zenatanehttps://practicaldermatology.com/news/20140715-promius_pharma_launches_new_physician_portal_to_track_patient_progress_on_zenatane/2459169/A new web-based provider portal from Promius Pharma allows physicians to follow a patient's progress while taking Zenatane™(isotretinoin capsules USP) AB rated to Accutane. Designed to allow any authorized prescriber using the Promius Promise to obtain easy, instant access to secure patient data rel
- KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Applicationhttps://practicaldermatology.com/news/20140711-kythera_biopharmaceuticals_announces_fda_acceptance_of_atx-101_new_drug_application/2459173/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficien
- PuraCap Pharmaceutical Introduces EpiCeram 225g Airless Pumphttps://practicaldermatology.com/news/20140711-puracap_pharmaceutical_introduces_epiceram_225g_airless_pump/2459174/PuraCap Pharmaceutical introduced the newest addition to the EpiCeram product line, the EpiCeram 225g Airless Pump. The airless pump gives patients more EpiCeram to treat any size area of atopi
- Galderma Finalizes Expansion in Aesthetic and Corrective Dermatologyhttps://practicaldermatology.com/news/20140710-galderma_finalizes_expansion_in_aesthetic_and_corrective_dermatology/2459175/Galderma S.A. has gained full rights to distribute Restylane, Perlane, Emervel, Sculptra, and Dysport from Valeant Pharmaceuticals International, Inc. “We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and
- FDA Grants Orphan Drug Designation for Galderma's Trifarotene Molecule to Treat Congenital Ichthyosishttps://practicaldermatology.com/news/20140702-fda_grants_orphan_drug_designation_for_galdermas_trifarotene_molecule_to_treat_congenital_ichthyosis/2459180/The FDA granted orphan drug designation status for Galderma's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma says it pla
- FDA Warns on Acne Productshttps://practicaldermatology.com/news/20140627-fda_warns_on_acne_products/2459185/The FDA warns that using certain acne products containing benzoyl peroxide or salicylic acid can cause rare, but serious and in some cases life-threatening allergic reactions or severe irritation. Certain topical solutions cause: burning, dryness, itching, peeling, redness, and slight sw
- New National Psoriasis Foundation Program Prioritizes Psoriatic Arthritishttps://practicaldermatology.com/news/20140626-new_national_psoriasis_foundation_program_prioritizes_psoriatic_arthritis/2459186/According to the National Psoriasis Foundation (NPF), millions of Americans with psoriatic arthritis struggle to get the health care and treatments they need to manage their condition. To help change that, the NPF launched the largest realignment and expansion of its psoriatic a
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459200/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allerg
- Celsus Therapeutics Receives Ministry of Health of Israel Approval to Conduct Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/20140617-a_new_class_of_treatment_can_to_be_used_for_atopic_dermatitis/2459202/Celsus Therapeutics Plc received approval from Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients. The Company plans to conduct the study in five to six centers in Israel as well as Argentina. They plan to enroll 80 pediatric patient